primary ipla2 (rabbit polyclonal) antibody Search Results


for cpla2  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc for cpla2
Fig. 1. Analysis of <t>cPLA2-alpha</t> and <t>iPLA2-beta</t> expression according to disease stage. A: A representative blot from a Western blotting analysis is shown. B: Mean expression normalized to actin for n = 12 controls and n = 56 patients, as determined by densitometry analysis. Control stands for healthy B CD5 positive cells (N95% purity as ascertained by flow cytometry).
For Cpla2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+ipla2+(rabbit+polyclonal)+antibody/cPLA2+Antibody/pm25072959-63-41-38
Average 96 stars, based on 1 article reviews
for cpla2 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
rabbit anti atgl  (Proteintech)
96
Proteintech rabbit anti atgl
Fig. 1. Analysis of <t>cPLA2-alpha</t> and <t>iPLA2-beta</t> expression according to disease stage. A: A representative blot from a Western blotting analysis is shown. B: Mean expression normalized to actin for n = 12 controls and n = 56 patients, as determined by densitometry analysis. Control stands for healthy B CD5 positive cells (N95% purity as ascertained by flow cytometry).
Rabbit Anti Atgl, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+ipla2+(rabbit+polyclonal)+antibody/ATGL+Antibody/pmc12464335-10-0-4
Average 96 stars, based on 1 article reviews
rabbit anti atgl - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
rat  (Proteintech)
93
Proteintech rat
Fig. 1. Analysis of <t>cPLA2-alpha</t> and <t>iPLA2-beta</t> expression according to disease stage. A: A representative blot from a Western blotting analysis is shown. B: Mean expression normalized to actin for n = 12 controls and n = 56 patients, as determined by densitometry analysis. Control stands for healthy B CD5 positive cells (N95% purity as ascertained by flow cytometry).
Rat, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+ipla2+(rabbit+polyclonal)+antibody/iPLA2+Antibody/pm37022709-412-15-26
Average 93 stars, based on 1 article reviews
rat - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
anti group vi ipla2  (Santa Cruz Biotechnology)
94
Santa Cruz Biotechnology anti group vi ipla2
MeCP2 lactylation regulates neuronal apoptosis after stroke. A) Heatmap depicting differential lactylation at specific lysine residues of proteins involved in the regulation of neuronal death after stroke. B) PRM quantification of MeCP2 K210 lactylation levels in the brains of sham and MCAO mice ( n = 3 mice per group). C) MeCP2 was immunoprecipitated from sham and MCAO brain tissues, and pan‐Kla and MeCP2 levels were analyzed by Western blot. D) Representative immunofluorescence images showing the proximity ligation assay used to validate MeCP2 lactylation in neurons within the cortex of MCAO mice. Red, in situ PLA detection of MeCP2 and pan‐Kla; green, NeuN; blue, DAPI. E) Heatmap showing differentially lactylated proteins involved in transcriptional regulation between sham and MCAO groups. F) The binding density of MeCP2 was visualized by deepTools: the heatmap presents the CUT&Tag counts at different MeCP2 binding peaks across different treatment groups, ordered by signal strength. G) Distribution of MeCP2 binding peaks across genomic regions in cortical tissues from sham‐operated mice and MCAO mice treated with saline, 2‐DG or 4‐CIN. H) GO enrichment analysis of downregulated and upregulated genes associated with MeCP2 binding sites in the penumbra from MCAO mice. I) Genome browser tracks of MeCP2 CUT&Tag peaks at Pdcd4 and <t>Pla2g6</t> loci across treatment groups. The purple rectangles indicate the peak regions of MeCP2 on target‐gene promoters. J) Luciferase reporter assay showing relative activity at Pdcd4 and Pla2g6 peaks in HEK293T cells expressing HA‐MeCP2 or HA‐GFP ( n = 3 per group). K) Western blot showing over‐expression of MeCP2 in HEK293 cells, with β‐actin as a loading control. L) Relative luciferase activity at Pdcd4 and Pla2g6 peaks in wild‐type (WT) and MeCP2 −/− HEK293T cells ( n = 4 per group). M) Motif enrichment analysis of MeCP2 binding sites, highlighting top enriched motifs with corresponding p ‐values. N) EMSA demonstrating MeCP2 binding to the CpG‐rich promoters of the target genes Pdcd4 and Pla2g6 . O) ChIP‐qPCR quantification of MeCP2 enrichment at Pdcd4 and Pla2g6 promoter in sham mice and MCAO mice treated with saline, 2‐DG or 4‐CIN ( n = 4 per group). P) Cortical expression of Pdcd4 and Pla2g6 determined by qPCR in sham mice and MCAO mice treated with saline, 2‐DG or 4‐CIN ( n = 5–6 per group). Data are presented as mean ± SEM. # p < 0.05 versus sham control; * p < 0.05, ** p < 0.01, *** p < 0.001 versus MCAO control; ns, not significant.
Anti Group Vi Ipla2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+ipla2+(rabbit+polyclonal)+antibody/group+VI+iPLA2+Antibody/pmc12140320-314-148-153
Average 94 stars, based on 1 article reviews
anti group vi ipla2 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
polyclonal rabbit antibody to ipla2η  (Proteintech)
91
Proteintech polyclonal rabbit antibody to ipla2η
MeCP2 lactylation regulates neuronal apoptosis after stroke. A) Heatmap depicting differential lactylation at specific lysine residues of proteins involved in the regulation of neuronal death after stroke. B) PRM quantification of MeCP2 K210 lactylation levels in the brains of sham and MCAO mice ( n = 3 mice per group). C) MeCP2 was immunoprecipitated from sham and MCAO brain tissues, and pan‐Kla and MeCP2 levels were analyzed by Western blot. D) Representative immunofluorescence images showing the proximity ligation assay used to validate MeCP2 lactylation in neurons within the cortex of MCAO mice. Red, in situ PLA detection of MeCP2 and pan‐Kla; green, NeuN; blue, DAPI. E) Heatmap showing differentially lactylated proteins involved in transcriptional regulation between sham and MCAO groups. F) The binding density of MeCP2 was visualized by deepTools: the heatmap presents the CUT&Tag counts at different MeCP2 binding peaks across different treatment groups, ordered by signal strength. G) Distribution of MeCP2 binding peaks across genomic regions in cortical tissues from sham‐operated mice and MCAO mice treated with saline, 2‐DG or 4‐CIN. H) GO enrichment analysis of downregulated and upregulated genes associated with MeCP2 binding sites in the penumbra from MCAO mice. I) Genome browser tracks of MeCP2 CUT&Tag peaks at Pdcd4 and <t>Pla2g6</t> loci across treatment groups. The purple rectangles indicate the peak regions of MeCP2 on target‐gene promoters. J) Luciferase reporter assay showing relative activity at Pdcd4 and Pla2g6 peaks in HEK293T cells expressing HA‐MeCP2 or HA‐GFP ( n = 3 per group). K) Western blot showing over‐expression of MeCP2 in HEK293 cells, with β‐actin as a loading control. L) Relative luciferase activity at Pdcd4 and Pla2g6 peaks in wild‐type (WT) and MeCP2 −/− HEK293T cells ( n = 4 per group). M) Motif enrichment analysis of MeCP2 binding sites, highlighting top enriched motifs with corresponding p ‐values. N) EMSA demonstrating MeCP2 binding to the CpG‐rich promoters of the target genes Pdcd4 and Pla2g6 . O) ChIP‐qPCR quantification of MeCP2 enrichment at Pdcd4 and Pla2g6 promoter in sham mice and MCAO mice treated with saline, 2‐DG or 4‐CIN ( n = 4 per group). P) Cortical expression of Pdcd4 and Pla2g6 determined by qPCR in sham mice and MCAO mice treated with saline, 2‐DG or 4‐CIN ( n = 5–6 per group). Data are presented as mean ± SEM. # p < 0.05 versus sham control; * p < 0.05, ** p < 0.01, *** p < 0.001 versus MCAO control; ns, not significant.
Polyclonal Rabbit Antibody To Ipla2η, supplied by Proteintech, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+ipla2+(rabbit+polyclonal)+antibody/PNPLA4+Antibody/pm37524709-352-69-75
Average 91 stars, based on 1 article reviews
polyclonal rabbit antibody to ipla2η - by Bioz Stars, 2026-09
91/100 stars
  Buy from Supplier
anti ipla2 gvia  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology anti ipla2 gvia
MeCP2 lactylation regulates neuronal apoptosis after stroke. A) Heatmap depicting differential lactylation at specific lysine residues of proteins involved in the regulation of neuronal death after stroke. B) PRM quantification of MeCP2 K210 lactylation levels in the brains of sham and MCAO mice ( n = 3 mice per group). C) MeCP2 was immunoprecipitated from sham and MCAO brain tissues, and pan‐Kla and MeCP2 levels were analyzed by Western blot. D) Representative immunofluorescence images showing the proximity ligation assay used to validate MeCP2 lactylation in neurons within the cortex of MCAO mice. Red, in situ PLA detection of MeCP2 and pan‐Kla; green, NeuN; blue, DAPI. E) Heatmap showing differentially lactylated proteins involved in transcriptional regulation between sham and MCAO groups. F) The binding density of MeCP2 was visualized by deepTools: the heatmap presents the CUT&Tag counts at different MeCP2 binding peaks across different treatment groups, ordered by signal strength. G) Distribution of MeCP2 binding peaks across genomic regions in cortical tissues from sham‐operated mice and MCAO mice treated with saline, 2‐DG or 4‐CIN. H) GO enrichment analysis of downregulated and upregulated genes associated with MeCP2 binding sites in the penumbra from MCAO mice. I) Genome browser tracks of MeCP2 CUT&Tag peaks at Pdcd4 and <t>Pla2g6</t> loci across treatment groups. The purple rectangles indicate the peak regions of MeCP2 on target‐gene promoters. J) Luciferase reporter assay showing relative activity at Pdcd4 and Pla2g6 peaks in HEK293T cells expressing HA‐MeCP2 or HA‐GFP ( n = 3 per group). K) Western blot showing over‐expression of MeCP2 in HEK293 cells, with β‐actin as a loading control. L) Relative luciferase activity at Pdcd4 and Pla2g6 peaks in wild‐type (WT) and MeCP2 −/− HEK293T cells ( n = 4 per group). M) Motif enrichment analysis of MeCP2 binding sites, highlighting top enriched motifs with corresponding p ‐values. N) EMSA demonstrating MeCP2 binding to the CpG‐rich promoters of the target genes Pdcd4 and Pla2g6 . O) ChIP‐qPCR quantification of MeCP2 enrichment at Pdcd4 and Pla2g6 promoter in sham mice and MCAO mice treated with saline, 2‐DG or 4‐CIN ( n = 4 per group). P) Cortical expression of Pdcd4 and Pla2g6 determined by qPCR in sham mice and MCAO mice treated with saline, 2‐DG or 4‐CIN ( n = 5–6 per group). Data are presented as mean ± SEM. # p < 0.05 versus sham control; * p < 0.05, ** p < 0.01, *** p < 0.001 versus MCAO control; ns, not significant.
Anti Ipla2 Gvia, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+ipla2+(rabbit+polyclonal)+antibody/sPLA2/us08420852-235-26-22
Average 93 stars, based on 1 article reviews
anti ipla2 gvia - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
ipla 2  (Novus Biologicals)
92
Novus Biologicals ipla 2
MeCP2 lactylation regulates neuronal apoptosis after stroke. A) Heatmap depicting differential lactylation at specific lysine residues of proteins involved in the regulation of neuronal death after stroke. B) PRM quantification of MeCP2 K210 lactylation levels in the brains of sham and MCAO mice ( n = 3 mice per group). C) MeCP2 was immunoprecipitated from sham and MCAO brain tissues, and pan‐Kla and MeCP2 levels were analyzed by Western blot. D) Representative immunofluorescence images showing the proximity ligation assay used to validate MeCP2 lactylation in neurons within the cortex of MCAO mice. Red, in situ PLA detection of MeCP2 and pan‐Kla; green, NeuN; blue, DAPI. E) Heatmap showing differentially lactylated proteins involved in transcriptional regulation between sham and MCAO groups. F) The binding density of MeCP2 was visualized by deepTools: the heatmap presents the CUT&Tag counts at different MeCP2 binding peaks across different treatment groups, ordered by signal strength. G) Distribution of MeCP2 binding peaks across genomic regions in cortical tissues from sham‐operated mice and MCAO mice treated with saline, 2‐DG or 4‐CIN. H) GO enrichment analysis of downregulated and upregulated genes associated with MeCP2 binding sites in the penumbra from MCAO mice. I) Genome browser tracks of MeCP2 CUT&Tag peaks at Pdcd4 and <t>Pla2g6</t> loci across treatment groups. The purple rectangles indicate the peak regions of MeCP2 on target‐gene promoters. J) Luciferase reporter assay showing relative activity at Pdcd4 and Pla2g6 peaks in HEK293T cells expressing HA‐MeCP2 or HA‐GFP ( n = 3 per group). K) Western blot showing over‐expression of MeCP2 in HEK293 cells, with β‐actin as a loading control. L) Relative luciferase activity at Pdcd4 and Pla2g6 peaks in wild‐type (WT) and MeCP2 −/− HEK293T cells ( n = 4 per group). M) Motif enrichment analysis of MeCP2 binding sites, highlighting top enriched motifs with corresponding p ‐values. N) EMSA demonstrating MeCP2 binding to the CpG‐rich promoters of the target genes Pdcd4 and Pla2g6 . O) ChIP‐qPCR quantification of MeCP2 enrichment at Pdcd4 and Pla2g6 promoter in sham mice and MCAO mice treated with saline, 2‐DG or 4‐CIN ( n = 4 per group). P) Cortical expression of Pdcd4 and Pla2g6 determined by qPCR in sham mice and MCAO mice treated with saline, 2‐DG or 4‐CIN ( n = 5–6 per group). Data are presented as mean ± SEM. # p < 0.05 versus sham control; * p < 0.05, ** p < 0.01, *** p < 0.001 versus MCAO control; ns, not significant.
Ipla 2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+ipla2+(rabbit+polyclonal)+antibody/PLA2G6+Antibody/pmc05530945-68-25-31
Average 92 stars, based on 1 article reviews
ipla 2 - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier
pnpla3  (Proteintech)
90
Proteintech pnpla3
MeCP2 lactylation regulates neuronal apoptosis after stroke. A) Heatmap depicting differential lactylation at specific lysine residues of proteins involved in the regulation of neuronal death after stroke. B) PRM quantification of MeCP2 K210 lactylation levels in the brains of sham and MCAO mice ( n = 3 mice per group). C) MeCP2 was immunoprecipitated from sham and MCAO brain tissues, and pan‐Kla and MeCP2 levels were analyzed by Western blot. D) Representative immunofluorescence images showing the proximity ligation assay used to validate MeCP2 lactylation in neurons within the cortex of MCAO mice. Red, in situ PLA detection of MeCP2 and pan‐Kla; green, NeuN; blue, DAPI. E) Heatmap showing differentially lactylated proteins involved in transcriptional regulation between sham and MCAO groups. F) The binding density of MeCP2 was visualized by deepTools: the heatmap presents the CUT&Tag counts at different MeCP2 binding peaks across different treatment groups, ordered by signal strength. G) Distribution of MeCP2 binding peaks across genomic regions in cortical tissues from sham‐operated mice and MCAO mice treated with saline, 2‐DG or 4‐CIN. H) GO enrichment analysis of downregulated and upregulated genes associated with MeCP2 binding sites in the penumbra from MCAO mice. I) Genome browser tracks of MeCP2 CUT&Tag peaks at Pdcd4 and <t>Pla2g6</t> loci across treatment groups. The purple rectangles indicate the peak regions of MeCP2 on target‐gene promoters. J) Luciferase reporter assay showing relative activity at Pdcd4 and Pla2g6 peaks in HEK293T cells expressing HA‐MeCP2 or HA‐GFP ( n = 3 per group). K) Western blot showing over‐expression of MeCP2 in HEK293 cells, with β‐actin as a loading control. L) Relative luciferase activity at Pdcd4 and Pla2g6 peaks in wild‐type (WT) and MeCP2 −/− HEK293T cells ( n = 4 per group). M) Motif enrichment analysis of MeCP2 binding sites, highlighting top enriched motifs with corresponding p ‐values. N) EMSA demonstrating MeCP2 binding to the CpG‐rich promoters of the target genes Pdcd4 and Pla2g6 . O) ChIP‐qPCR quantification of MeCP2 enrichment at Pdcd4 and Pla2g6 promoter in sham mice and MCAO mice treated with saline, 2‐DG or 4‐CIN ( n = 4 per group). P) Cortical expression of Pdcd4 and Pla2g6 determined by qPCR in sham mice and MCAO mice treated with saline, 2‐DG or 4‐CIN ( n = 5–6 per group). Data are presented as mean ± SEM. # p < 0.05 versus sham control; * p < 0.05, ** p < 0.01, *** p < 0.001 versus MCAO control; ns, not significant.
Pnpla3, supplied by Proteintech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+ipla2+(rabbit+polyclonal)+antibody/PNPLA3+Antibody/pm24718268-266-48-59
Average 90 stars, based on 1 article reviews
pnpla3 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
beta-actin antibody  (NSJ Bioreagents)
92
NSJ Bioreagents beta-actin antibody
MeCP2 lactylation regulates neuronal apoptosis after stroke. A) Heatmap depicting differential lactylation at specific lysine residues of proteins involved in the regulation of neuronal death after stroke. B) PRM quantification of MeCP2 K210 lactylation levels in the brains of sham and MCAO mice ( n = 3 mice per group). C) MeCP2 was immunoprecipitated from sham and MCAO brain tissues, and pan‐Kla and MeCP2 levels were analyzed by Western blot. D) Representative immunofluorescence images showing the proximity ligation assay used to validate MeCP2 lactylation in neurons within the cortex of MCAO mice. Red, in situ PLA detection of MeCP2 and pan‐Kla; green, NeuN; blue, DAPI. E) Heatmap showing differentially lactylated proteins involved in transcriptional regulation between sham and MCAO groups. F) The binding density of MeCP2 was visualized by deepTools: the heatmap presents the CUT&Tag counts at different MeCP2 binding peaks across different treatment groups, ordered by signal strength. G) Distribution of MeCP2 binding peaks across genomic regions in cortical tissues from sham‐operated mice and MCAO mice treated with saline, 2‐DG or 4‐CIN. H) GO enrichment analysis of downregulated and upregulated genes associated with MeCP2 binding sites in the penumbra from MCAO mice. I) Genome browser tracks of MeCP2 CUT&Tag peaks at Pdcd4 and <t>Pla2g6</t> loci across treatment groups. The purple rectangles indicate the peak regions of MeCP2 on target‐gene promoters. J) Luciferase reporter assay showing relative activity at Pdcd4 and Pla2g6 peaks in HEK293T cells expressing HA‐MeCP2 or HA‐GFP ( n = 3 per group). K) Western blot showing over‐expression of MeCP2 in HEK293 cells, with β‐actin as a loading control. L) Relative luciferase activity at Pdcd4 and Pla2g6 peaks in wild‐type (WT) and MeCP2 −/− HEK293T cells ( n = 4 per group). M) Motif enrichment analysis of MeCP2 binding sites, highlighting top enriched motifs with corresponding p ‐values. N) EMSA demonstrating MeCP2 binding to the CpG‐rich promoters of the target genes Pdcd4 and Pla2g6 . O) ChIP‐qPCR quantification of MeCP2 enrichment at Pdcd4 and Pla2g6 promoter in sham mice and MCAO mice treated with saline, 2‐DG or 4‐CIN ( n = 4 per group). P) Cortical expression of Pdcd4 and Pla2g6 determined by qPCR in sham mice and MCAO mice treated with saline, 2‐DG or 4‐CIN ( n = 5–6 per group). Data are presented as mean ± SEM. # p < 0.05 versus sham control; * p < 0.05, ** p < 0.01, *** p < 0.001 versus MCAO control; ns, not significant.
Beta Actin Antibody, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+ipla2+(rabbit+polyclonal)+antibody/Beta-Actin+Antibody/custom%40r30100%4022549787
Average 92 stars, based on 1 article reviews
beta-actin antibody - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier
monoclonal mouse antibody to ipla 2 ζ  (Abnova)
90
Abnova monoclonal mouse antibody to ipla 2 ζ
MeCP2 lactylation regulates neuronal apoptosis after stroke. A) Heatmap depicting differential lactylation at specific lysine residues of proteins involved in the regulation of neuronal death after stroke. B) PRM quantification of MeCP2 K210 lactylation levels in the brains of sham and MCAO mice ( n = 3 mice per group). C) MeCP2 was immunoprecipitated from sham and MCAO brain tissues, and pan‐Kla and MeCP2 levels were analyzed by Western blot. D) Representative immunofluorescence images showing the proximity ligation assay used to validate MeCP2 lactylation in neurons within the cortex of MCAO mice. Red, in situ PLA detection of MeCP2 and pan‐Kla; green, NeuN; blue, DAPI. E) Heatmap showing differentially lactylated proteins involved in transcriptional regulation between sham and MCAO groups. F) The binding density of MeCP2 was visualized by deepTools: the heatmap presents the CUT&Tag counts at different MeCP2 binding peaks across different treatment groups, ordered by signal strength. G) Distribution of MeCP2 binding peaks across genomic regions in cortical tissues from sham‐operated mice and MCAO mice treated with saline, 2‐DG or 4‐CIN. H) GO enrichment analysis of downregulated and upregulated genes associated with MeCP2 binding sites in the penumbra from MCAO mice. I) Genome browser tracks of MeCP2 CUT&Tag peaks at Pdcd4 and <t>Pla2g6</t> loci across treatment groups. The purple rectangles indicate the peak regions of MeCP2 on target‐gene promoters. J) Luciferase reporter assay showing relative activity at Pdcd4 and Pla2g6 peaks in HEK293T cells expressing HA‐MeCP2 or HA‐GFP ( n = 3 per group). K) Western blot showing over‐expression of MeCP2 in HEK293 cells, with β‐actin as a loading control. L) Relative luciferase activity at Pdcd4 and Pla2g6 peaks in wild‐type (WT) and MeCP2 −/− HEK293T cells ( n = 4 per group). M) Motif enrichment analysis of MeCP2 binding sites, highlighting top enriched motifs with corresponding p ‐values. N) EMSA demonstrating MeCP2 binding to the CpG‐rich promoters of the target genes Pdcd4 and Pla2g6 . O) ChIP‐qPCR quantification of MeCP2 enrichment at Pdcd4 and Pla2g6 promoter in sham mice and MCAO mice treated with saline, 2‐DG or 4‐CIN ( n = 4 per group). P) Cortical expression of Pdcd4 and Pla2g6 determined by qPCR in sham mice and MCAO mice treated with saline, 2‐DG or 4‐CIN ( n = 5–6 per group). Data are presented as mean ± SEM. # p < 0.05 versus sham control; * p < 0.05, ** p < 0.01, *** p < 0.001 versus MCAO control; ns, not significant.
Monoclonal Mouse Antibody To Ipla 2 ζ, supplied by Abnova, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+ipla2+(rabbit+polyclonal)+antibody/monoclonal+mouse+antibody+ipla+2+%CE%B6/pmc10390482-297-51-55
Average 90 stars, based on 1 article reviews
monoclonal mouse antibody to ipla 2 ζ - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
monoclonal mouse antibody to glyceraldehyde-3-phosphate dehydrogenase (gapdh)  (FUJIFILM)
90
FUJIFILM monoclonal mouse antibody to glyceraldehyde-3-phosphate dehydrogenase (gapdh)
MeCP2 lactylation regulates neuronal apoptosis after stroke. A) Heatmap depicting differential lactylation at specific lysine residues of proteins involved in the regulation of neuronal death after stroke. B) PRM quantification of MeCP2 K210 lactylation levels in the brains of sham and MCAO mice ( n = 3 mice per group). C) MeCP2 was immunoprecipitated from sham and MCAO brain tissues, and pan‐Kla and MeCP2 levels were analyzed by Western blot. D) Representative immunofluorescence images showing the proximity ligation assay used to validate MeCP2 lactylation in neurons within the cortex of MCAO mice. Red, in situ PLA detection of MeCP2 and pan‐Kla; green, NeuN; blue, DAPI. E) Heatmap showing differentially lactylated proteins involved in transcriptional regulation between sham and MCAO groups. F) The binding density of MeCP2 was visualized by deepTools: the heatmap presents the CUT&Tag counts at different MeCP2 binding peaks across different treatment groups, ordered by signal strength. G) Distribution of MeCP2 binding peaks across genomic regions in cortical tissues from sham‐operated mice and MCAO mice treated with saline, 2‐DG or 4‐CIN. H) GO enrichment analysis of downregulated and upregulated genes associated with MeCP2 binding sites in the penumbra from MCAO mice. I) Genome browser tracks of MeCP2 CUT&Tag peaks at Pdcd4 and <t>Pla2g6</t> loci across treatment groups. The purple rectangles indicate the peak regions of MeCP2 on target‐gene promoters. J) Luciferase reporter assay showing relative activity at Pdcd4 and Pla2g6 peaks in HEK293T cells expressing HA‐MeCP2 or HA‐GFP ( n = 3 per group). K) Western blot showing over‐expression of MeCP2 in HEK293 cells, with β‐actin as a loading control. L) Relative luciferase activity at Pdcd4 and Pla2g6 peaks in wild‐type (WT) and MeCP2 −/− HEK293T cells ( n = 4 per group). M) Motif enrichment analysis of MeCP2 binding sites, highlighting top enriched motifs with corresponding p ‐values. N) EMSA demonstrating MeCP2 binding to the CpG‐rich promoters of the target genes Pdcd4 and Pla2g6 . O) ChIP‐qPCR quantification of MeCP2 enrichment at Pdcd4 and Pla2g6 promoter in sham mice and MCAO mice treated with saline, 2‐DG or 4‐CIN ( n = 4 per group). P) Cortical expression of Pdcd4 and Pla2g6 determined by qPCR in sham mice and MCAO mice treated with saline, 2‐DG or 4‐CIN ( n = 5–6 per group). Data are presented as mean ± SEM. # p < 0.05 versus sham control; * p < 0.05, ** p < 0.01, *** p < 0.001 versus MCAO control; ns, not significant.
Monoclonal Mouse Antibody To Glyceraldehyde 3 Phosphate Dehydrogenase (Gapdh), supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+ipla2+(rabbit+polyclonal)+antibody/anti+gapdh/pmc10390482-297-31-35
Average 90 stars, based on 1 article reviews
monoclonal mouse antibody to glyceraldehyde-3-phosphate dehydrogenase (gapdh) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
anti-ipla 2  (Becton Dickinson)
90
Becton Dickinson anti-ipla 2
Mean ± SD of the fatty acid hydrolysis
Anti Ipla 2, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+ipla2+(rabbit+polyclonal)+antibody/recombinant+ipla2/pmc02677793-104-14-31
Average 90 stars, based on 1 article reviews
anti-ipla 2 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Fig. 1. Analysis of cPLA2-alpha and iPLA2-beta expression according to disease stage. A: A representative blot from a Western blotting analysis is shown. B: Mean expression normalized to actin for n = 12 controls and n = 56 patients, as determined by densitometry analysis. Control stands for healthy B CD5 positive cells (N95% purity as ascertained by flow cytometry).

Journal: Biochimica et biophysica acta

Article Title: The arachidonic acid-LTB4-BLT2 pathway enhances human B-CLL aggressiveness.

doi: 10.1016/j.bbadis.2014.07.016

Figure Lengend Snippet: Fig. 1. Analysis of cPLA2-alpha and iPLA2-beta expression according to disease stage. A: A representative blot from a Western blotting analysis is shown. B: Mean expression normalized to actin for n = 12 controls and n = 56 patients, as determined by densitometry analysis. Control stands for healthy B CD5 positive cells (N95% purity as ascertained by flow cytometry).

Article Snippet: Primary antibodies were purchased from Abcam for anti-actin (catalog number ab1801, rabbit polyclonal), iPLA2 (ab23706, rabbit polyclonal, does not cross-react with cPLA2 or sPLA2), pan-PLA2 (ab9014, sheep polyclonal), COX1 (ab695, mouse monoclonal), and COX2 (ab15191, rabbit polyclonal), from cell signaling technology for cPLA2 (catalog number 2832, rabbit polyclonal, does not cross-react with iPLA2 or sPLA2).

Techniques: Expressing, Western Blot, Control, Cytometry

Fig. 2. Analysis of cPLA2-alpha and iPL2-beta expression and disease progression. Analysis over a 36 months follow-up for slowly progressing (A, n = 24) or 24 months follow-up for rap- idly progressing (B, n = 19) disease. Two representative series of analyses are shown per group of patients. C and D: Mean expression normalized to actin (densitometry analysis) for patients with a slowly progressing disease (C, n = 24) or a highly progressing disease (D, n = 19).

Journal: Biochimica et biophysica acta

Article Title: The arachidonic acid-LTB4-BLT2 pathway enhances human B-CLL aggressiveness.

doi: 10.1016/j.bbadis.2014.07.016

Figure Lengend Snippet: Fig. 2. Analysis of cPLA2-alpha and iPL2-beta expression and disease progression. Analysis over a 36 months follow-up for slowly progressing (A, n = 24) or 24 months follow-up for rap- idly progressing (B, n = 19) disease. Two representative series of analyses are shown per group of patients. C and D: Mean expression normalized to actin (densitometry analysis) for patients with a slowly progressing disease (C, n = 24) or a highly progressing disease (D, n = 19).

Article Snippet: Primary antibodies were purchased from Abcam for anti-actin (catalog number ab1801, rabbit polyclonal), iPLA2 (ab23706, rabbit polyclonal, does not cross-react with cPLA2 or sPLA2), pan-PLA2 (ab9014, sheep polyclonal), COX1 (ab695, mouse monoclonal), and COX2 (ab15191, rabbit polyclonal), from cell signaling technology for cPLA2 (catalog number 2832, rabbit polyclonal, does not cross-react with iPLA2 or sPLA2).

Techniques: Expressing, Biomarker Discovery

MeCP2 lactylation regulates neuronal apoptosis after stroke. A) Heatmap depicting differential lactylation at specific lysine residues of proteins involved in the regulation of neuronal death after stroke. B) PRM quantification of MeCP2 K210 lactylation levels in the brains of sham and MCAO mice ( n = 3 mice per group). C) MeCP2 was immunoprecipitated from sham and MCAO brain tissues, and pan‐Kla and MeCP2 levels were analyzed by Western blot. D) Representative immunofluorescence images showing the proximity ligation assay used to validate MeCP2 lactylation in neurons within the cortex of MCAO mice. Red, in situ PLA detection of MeCP2 and pan‐Kla; green, NeuN; blue, DAPI. E) Heatmap showing differentially lactylated proteins involved in transcriptional regulation between sham and MCAO groups. F) The binding density of MeCP2 was visualized by deepTools: the heatmap presents the CUT&Tag counts at different MeCP2 binding peaks across different treatment groups, ordered by signal strength. G) Distribution of MeCP2 binding peaks across genomic regions in cortical tissues from sham‐operated mice and MCAO mice treated with saline, 2‐DG or 4‐CIN. H) GO enrichment analysis of downregulated and upregulated genes associated with MeCP2 binding sites in the penumbra from MCAO mice. I) Genome browser tracks of MeCP2 CUT&Tag peaks at Pdcd4 and Pla2g6 loci across treatment groups. The purple rectangles indicate the peak regions of MeCP2 on target‐gene promoters. J) Luciferase reporter assay showing relative activity at Pdcd4 and Pla2g6 peaks in HEK293T cells expressing HA‐MeCP2 or HA‐GFP ( n = 3 per group). K) Western blot showing over‐expression of MeCP2 in HEK293 cells, with β‐actin as a loading control. L) Relative luciferase activity at Pdcd4 and Pla2g6 peaks in wild‐type (WT) and MeCP2 −/− HEK293T cells ( n = 4 per group). M) Motif enrichment analysis of MeCP2 binding sites, highlighting top enriched motifs with corresponding p ‐values. N) EMSA demonstrating MeCP2 binding to the CpG‐rich promoters of the target genes Pdcd4 and Pla2g6 . O) ChIP‐qPCR quantification of MeCP2 enrichment at Pdcd4 and Pla2g6 promoter in sham mice and MCAO mice treated with saline, 2‐DG or 4‐CIN ( n = 4 per group). P) Cortical expression of Pdcd4 and Pla2g6 determined by qPCR in sham mice and MCAO mice treated with saline, 2‐DG or 4‐CIN ( n = 5–6 per group). Data are presented as mean ± SEM. # p < 0.05 versus sham control; * p < 0.05, ** p < 0.01, *** p < 0.001 versus MCAO control; ns, not significant.

Journal: Advanced Science

Article Title: MeCP2 Lactylation Protects against Ischemic Brain Injury by Transcriptionally Regulating Neuronal Apoptosis

doi: 10.1002/advs.202415309

Figure Lengend Snippet: MeCP2 lactylation regulates neuronal apoptosis after stroke. A) Heatmap depicting differential lactylation at specific lysine residues of proteins involved in the regulation of neuronal death after stroke. B) PRM quantification of MeCP2 K210 lactylation levels in the brains of sham and MCAO mice ( n = 3 mice per group). C) MeCP2 was immunoprecipitated from sham and MCAO brain tissues, and pan‐Kla and MeCP2 levels were analyzed by Western blot. D) Representative immunofluorescence images showing the proximity ligation assay used to validate MeCP2 lactylation in neurons within the cortex of MCAO mice. Red, in situ PLA detection of MeCP2 and pan‐Kla; green, NeuN; blue, DAPI. E) Heatmap showing differentially lactylated proteins involved in transcriptional regulation between sham and MCAO groups. F) The binding density of MeCP2 was visualized by deepTools: the heatmap presents the CUT&Tag counts at different MeCP2 binding peaks across different treatment groups, ordered by signal strength. G) Distribution of MeCP2 binding peaks across genomic regions in cortical tissues from sham‐operated mice and MCAO mice treated with saline, 2‐DG or 4‐CIN. H) GO enrichment analysis of downregulated and upregulated genes associated with MeCP2 binding sites in the penumbra from MCAO mice. I) Genome browser tracks of MeCP2 CUT&Tag peaks at Pdcd4 and Pla2g6 loci across treatment groups. The purple rectangles indicate the peak regions of MeCP2 on target‐gene promoters. J) Luciferase reporter assay showing relative activity at Pdcd4 and Pla2g6 peaks in HEK293T cells expressing HA‐MeCP2 or HA‐GFP ( n = 3 per group). K) Western blot showing over‐expression of MeCP2 in HEK293 cells, with β‐actin as a loading control. L) Relative luciferase activity at Pdcd4 and Pla2g6 peaks in wild‐type (WT) and MeCP2 −/− HEK293T cells ( n = 4 per group). M) Motif enrichment analysis of MeCP2 binding sites, highlighting top enriched motifs with corresponding p ‐values. N) EMSA demonstrating MeCP2 binding to the CpG‐rich promoters of the target genes Pdcd4 and Pla2g6 . O) ChIP‐qPCR quantification of MeCP2 enrichment at Pdcd4 and Pla2g6 promoter in sham mice and MCAO mice treated with saline, 2‐DG or 4‐CIN ( n = 4 per group). P) Cortical expression of Pdcd4 and Pla2g6 determined by qPCR in sham mice and MCAO mice treated with saline, 2‐DG or 4‐CIN ( n = 5–6 per group). Data are presented as mean ± SEM. # p < 0.05 versus sham control; * p < 0.05, ** p < 0.01, *** p < 0.001 versus MCAO control; ns, not significant.

Article Snippet: The following primary antibodies were used: Anti‐L‐Lactyl Lysine Rabbit mAb (Cat. PTM‐1401, PTM BIO, China), Anti‐lacty‐MeCP2(Lys210) rabbit pAb (PTM BIO, China), Anti‐lacty‐MeCP2(Lys249) rabbit pAb (PTM BIO, China), Rabbit monoclonal anti‐MeCP2 (Cat. 3456, Cell Signaling Technology, USA), Rabbit monoclonal anti‐PDCD4 (Cat. 9535, Cell Signaling Technology, USA), Rabbit monoclonal anti‐HA‐Tag (Cat. 3724, Cell Signaling Technology, USA), Rabbit polyclonal anti‐Cleaved Caspase‐3 (Cat. 9661, Cell Signaling Technology, USA), Rabbit monoclonal anti‐HDAC1 (Cat. 34589, Cell Signaling Technology, USA), Mouse monoclonal anti‐HDAC2 (Cat. 5113, Cell Signaling Technology, USA), Mouse monoclonal anti‐HDAC3 (Cat. 3949, Cell Signaling Technology, USA), Rabbit monoclonal anti‐CHOP (Cat. 5554, Cell Signaling Technology, USA), Rabbit monoclonal anti‐Caspase‐1 (Cat. 24232, Cell Signaling Technology, USA), Rabbit monoclonal anti‐Phospho‐RIP3 (Thr231/Ser232) (Cat. 91702, Cell Signaling Technology, USA), Mouse monoclonal anti‐AlaRS (Cat. sc‐165990, Santa Cruz Biotechnology, USA), Mouse monoclonal anti‐p300 (Cat. sc‐48343, Santa Cruz Biotechnology, USA), Mouse monoclonal anti‐CBP (Cat. sc‐7300, Santa Cruz Biotechnology, USA), Mouse monoclonal anti‐group VI iPLA2 (Cat. sc‐376563, Santa Cruz Biotechnology, USA), Mouse monoclonal anti‐PCAF (Cat. sc‐13124, Santa Cruz Biotechnology, USA), Mouse monoclonal anti‐KAT2A/GCN5(Cat. 66575‐1‐lg, Proteintech, China), Rabbit polyclonal anti‐RIP3 (Cat. 17563‐1‐lg, Proteintech, China), Mouse monoclonal anti‐b‐actin (Cat. 66009‐1‐lg, Proteintech, China), Mouse GAPDH Monoclonal antibodies (Cat. 60004‐1‐Ig, Protsintech, China).

Techniques: Immunoprecipitation, Western Blot, Immunofluorescence, Proximity Ligation Assay, In Situ, Binding Assay, Saline, Luciferase, Reporter Assay, Activity Assay, Expressing, Over Expression, Control, ChIP-qPCR

Lactylation of MeCP2 at K210 and K249 regulates apoptotic gene expression in stroke. A) Sequence alignment of the transcriptional repression domain of MeCP2 across species, highlighting conserved MeCP2 lactylation sites. B) Co‐immunoprecipitation and Western blot analysis showing reduced MeCP2 lactylation levels upon K210R or K249R mutation. Luciferase reporter assays showing increased transcriptional activity at the C) Pdcd4 and D) Pla2g6 promoters in HEK293T cells expressing K210R or K249R MeCP2 mutants compared to wild‐type MeCP2 ( n = 3 per group). E) MeCP2 was immunoprecipitated with anti‐HA from HEK293T cells expressing WT or K210R/K249R mutants, and pan‐Kla and HA‐MeCP2 levels were detected by Western blot. Luciferase reporter assays showing transcriptional activity at the F) Pdcd4 and G) Pla2g6 promoters in HEK293T cells expressing WT MeCP2 or K210/K249 mutants ( n = 4 per group). H) EMSA analysis showing recombinant wild‐type and mutant MeCP2 binding to the CpG‐rich promoters of Pdcd4 and Pla2g6 . I,J) Western blot analysis of cleaved caspase‐3 levels in primary neurons expressing wild‐type MeCP2, or MeCP2 mutants under OGD/R conditions ( n = 4–7 per group). K–M) Western blot analysis of GVI PLA2 and PDCD4 protein levels in neurons expressing wild‐type MeCP2, or MeCP2 mutants under OGD/R conditions ( n = 7–8 per group). Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001; ns, not significant.

Journal: Advanced Science

Article Title: MeCP2 Lactylation Protects against Ischemic Brain Injury by Transcriptionally Regulating Neuronal Apoptosis

doi: 10.1002/advs.202415309

Figure Lengend Snippet: Lactylation of MeCP2 at K210 and K249 regulates apoptotic gene expression in stroke. A) Sequence alignment of the transcriptional repression domain of MeCP2 across species, highlighting conserved MeCP2 lactylation sites. B) Co‐immunoprecipitation and Western blot analysis showing reduced MeCP2 lactylation levels upon K210R or K249R mutation. Luciferase reporter assays showing increased transcriptional activity at the C) Pdcd4 and D) Pla2g6 promoters in HEK293T cells expressing K210R or K249R MeCP2 mutants compared to wild‐type MeCP2 ( n = 3 per group). E) MeCP2 was immunoprecipitated with anti‐HA from HEK293T cells expressing WT or K210R/K249R mutants, and pan‐Kla and HA‐MeCP2 levels were detected by Western blot. Luciferase reporter assays showing transcriptional activity at the F) Pdcd4 and G) Pla2g6 promoters in HEK293T cells expressing WT MeCP2 or K210/K249 mutants ( n = 4 per group). H) EMSA analysis showing recombinant wild‐type and mutant MeCP2 binding to the CpG‐rich promoters of Pdcd4 and Pla2g6 . I,J) Western blot analysis of cleaved caspase‐3 levels in primary neurons expressing wild‐type MeCP2, or MeCP2 mutants under OGD/R conditions ( n = 4–7 per group). K–M) Western blot analysis of GVI PLA2 and PDCD4 protein levels in neurons expressing wild‐type MeCP2, or MeCP2 mutants under OGD/R conditions ( n = 7–8 per group). Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001; ns, not significant.

Article Snippet: The following primary antibodies were used: Anti‐L‐Lactyl Lysine Rabbit mAb (Cat. PTM‐1401, PTM BIO, China), Anti‐lacty‐MeCP2(Lys210) rabbit pAb (PTM BIO, China), Anti‐lacty‐MeCP2(Lys249) rabbit pAb (PTM BIO, China), Rabbit monoclonal anti‐MeCP2 (Cat. 3456, Cell Signaling Technology, USA), Rabbit monoclonal anti‐PDCD4 (Cat. 9535, Cell Signaling Technology, USA), Rabbit monoclonal anti‐HA‐Tag (Cat. 3724, Cell Signaling Technology, USA), Rabbit polyclonal anti‐Cleaved Caspase‐3 (Cat. 9661, Cell Signaling Technology, USA), Rabbit monoclonal anti‐HDAC1 (Cat. 34589, Cell Signaling Technology, USA), Mouse monoclonal anti‐HDAC2 (Cat. 5113, Cell Signaling Technology, USA), Mouse monoclonal anti‐HDAC3 (Cat. 3949, Cell Signaling Technology, USA), Rabbit monoclonal anti‐CHOP (Cat. 5554, Cell Signaling Technology, USA), Rabbit monoclonal anti‐Caspase‐1 (Cat. 24232, Cell Signaling Technology, USA), Rabbit monoclonal anti‐Phospho‐RIP3 (Thr231/Ser232) (Cat. 91702, Cell Signaling Technology, USA), Mouse monoclonal anti‐AlaRS (Cat. sc‐165990, Santa Cruz Biotechnology, USA), Mouse monoclonal anti‐p300 (Cat. sc‐48343, Santa Cruz Biotechnology, USA), Mouse monoclonal anti‐CBP (Cat. sc‐7300, Santa Cruz Biotechnology, USA), Mouse monoclonal anti‐group VI iPLA2 (Cat. sc‐376563, Santa Cruz Biotechnology, USA), Mouse monoclonal anti‐PCAF (Cat. sc‐13124, Santa Cruz Biotechnology, USA), Mouse monoclonal anti‐KAT2A/GCN5(Cat. 66575‐1‐lg, Proteintech, China), Rabbit polyclonal anti‐RIP3 (Cat. 17563‐1‐lg, Proteintech, China), Mouse monoclonal anti‐b‐actin (Cat. 66009‐1‐lg, Proteintech, China), Mouse GAPDH Monoclonal antibodies (Cat. 60004‐1‐Ig, Protsintech, China).

Techniques: Gene Expression, Sequencing, Immunoprecipitation, Western Blot, Mutagenesis, Luciferase, Activity Assay, Expressing, Recombinant, Binding Assay

Mean ± SD of the fatty acid hydrolysis

Journal:

Article Title: Differing roles for members of the phospholipase A 2 superfamily in experimental autoimmune encephalomyelitis

doi: 10.1093/brain/awp002

Figure Lengend Snippet: Mean ± SD of the fatty acid hydrolysis

Article Snippet: These cells were then stained with the following antibodies: Polyclonal rabbit anti-cPLA 2 , anti-iPLA 2 , anti-sPLA 2 IIA and anti-sPLA 2 V; monoclonal, FITC-conjugated anti-CD4, anti-CD8, anti-Mac-1/CD11b and anti-CD11c, (BD Pharmingen, 1:200).

Techniques: